Association of fluvoxamine with mortality and symptom resolution among inpatients with COVID-19 in Uganda: a prospective interventional open-label cohort study.
Journal
Molecular psychiatry
ISSN: 1476-5578
Titre abrégé: Mol Psychiatry
Pays: England
ID NLM: 9607835
Informations de publication
Date de publication:
03 Mar 2023
03 Mar 2023
Historique:
received:
17
11
2022
accepted:
15
02
2023
revised:
08
02
2023
entrez:
3
3
2023
pubmed:
4
3
2023
medline:
4
3
2023
Statut:
aheadofprint
Résumé
Prior research suggests that fluvoxamine, a selective serotonin reuptake inhibitor (SSRI) used for the treatment of obsessive-compulsive disorder and major depressive disorder, could be repurposed against COVID-19. We undertook a prospective interventional open-label cohort study to evaluate the efficacy and tolerability of fluvoxamine among inpatients with laboratory-confirmed COVID-19 in Uganda. The main outcome was all-cause mortality. Secondary outcomes were hospital discharge and complete symptom resolution. We included 316 patients, of whom 94 received fluvoxamine in addition to standard care [median age, 60 years (IQR = 37.0); women, 52.2%]. Fluvoxamine use was significantly associated with reduced mortality [AHR = 0.32; 95% CI = 0.19-0.53; p < 0.001, NNT = 4.46] and with increased complete symptom resolution [AOR = 2.56; 95% CI = 1.53-5.51; p < 0.001, NNT = 4.44]. Sensitivity analyses yielded similar results. These effects did not significantly differ by clinical characteristic, including vaccination status. Among the 161 survivors, fluvoxamine was not significantly associated with time to hospital discharge [AHR 0.81, 95% CI (0.54-1.23), p = 0.32]. There was a trend toward greater side effects with fluvoxamine (7.45% versus 3.15%; SMD = 0.21; χ
Identifiants
pubmed: 36869228
doi: 10.1038/s41380-023-02004-3
pii: 10.1038/s41380-023-02004-3
pmc: PMC9982784
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023. The Author(s).
Références
PLoS One. 2021 Feb 19;16(2):e0247122
pubmed: 33606790
Clin Microbiol Infect. 2023 Jan 16;:
pubmed: 36657488
Mol Psychiatry. 2022 Apr;27(4):1898-1907
pubmed: 34997196
Epidemiol Psychiatr Sci. 2022 Mar 30;31:e18
pubmed: 35352674
Cell Rep Med. 2020 Nov 17;1(8):100142
pubmed: 33163980
Mol Psychiatry. 2021 Dec;26(12):7098-7099
pubmed: 34385600
J Virol. 2022 Dec 21;96(24):e0124522
pubmed: 36468859
Encephale. 2020 Jun;46(3):193-201
pubmed: 32370982
Mol Psychiatry. 2022 Jan;27(1):307-314
pubmed: 34608263
Lancet. 2022 Apr 16;399(10334):1513-1536
pubmed: 35279232
Nat Med. 2013 Jul;19(7):934-8
pubmed: 23770692
Sci Rep. 2021 Mar 15;11(1):5890
pubmed: 33723270
Open Forum Infect Dis. 2021 Feb 01;8(2):ofab050
pubmed: 33623808
JAMA. 2020 Dec 8;324(22):2292-2300
pubmed: 33180097
Mol Psychiatry. 2022 Mar;27(3):1278-1280
pubmed: 34837060
Int J Pharm. 2021 Sep 25;607:121023
pubmed: 34416332
JAMA Netw Open. 2021 Nov 1;4(11):e2133090
pubmed: 34779847
Int J Mol Sci. 2022 Nov 07;23(21):
pubmed: 36362409
Risk Manag Healthc Policy. 2021 Nov 12;14:4609-4617
pubmed: 34803412
Clin Drug Investig. 2021 Mar;41(3):221-233
pubmed: 33559821
Open Forum Infect Dis. 2022 Aug 03;9(8):ofac389
pubmed: 36000003
JAMA Netw Open. 2022 Nov 1;5(11):e2242140
pubmed: 36378313
J Biol Chem. 2021 Jan-Jun;296:100701
pubmed: 33895135
Nat Med. 2020 Sep;26(9):1417-1421
pubmed: 32665655
Microorganisms. 2021 Feb 09;9(2):
pubmed: 33572117
Perspect Clin Res. 2016 Jan-Mar;7(1):51-3
pubmed: 26952180
Lancet. 2018 Apr 7;391(10128):1357-1366
pubmed: 29477251
JAMA Netw Open. 2022 Apr 1;5(4):e226269
pubmed: 35385087
Ann Med. 2022 Dec;54(1):516-523
pubmed: 35118917
Emerg Microbes Infect. 2020 Dec;9(1):2245-2255
pubmed: 32975484
Front Pharmacol. 2021 Apr 20;12:652688
pubmed: 33959018
Sci Transl Med. 2019 Feb 6;11(478):
pubmed: 30728287
Postgrad Med J. 1973 Nov;49(577):771-6
pubmed: 4806395
Br J Pharmacol. 2021 Jun;178(11):2339-2350
pubmed: 33825201
Eur J Pharmacol. 2014 Mar 15;727:167-73
pubmed: 24508523
JAMA Netw Open. 2021 Nov 1;4(11):e2136510
pubmed: 34779851
Transl Psychiatry. 2022 Aug 22;12(1):341
pubmed: 35995770
J Infect. 2023 Feb;86(2):154-225
pubmed: 36403698
Br J Clin Pharmacol. 2022 May;88(5):2065-2073
pubmed: 34719789
Mol Psychiatry. 2021 Sep;26(9):5199-5212
pubmed: 33536545
Clin Pharmacol Ther. 2021 Dec;110(6):1498-1511
pubmed: 34050932
Transl Psychiatry. 2022 Mar 3;12(1):90
pubmed: 35241663
Trends Pharmacol Sci. 2019 Sep;40(9):636-654
pubmed: 31387763
Crit Rev Clin Lab Sci. 2020 Sep;57(6):365-388
pubmed: 32645276
Lancet Glob Health. 2022 Mar;10(3):e333
pubmed: 35180413
Pharmaceutics. 2021 Sep 03;13(9):
pubmed: 34575474
J Clin Med. 2022 Oct 05;11(19):
pubmed: 36233753
Epidemiology. 2000 Sep;11(5):550-60
pubmed: 10955408
BMJ Open Respir Res. 2020 Sep;7(1):
pubmed: 32900781
Ann Intern Med. 2021 Nov;174(11):ITC161-ITC176
pubmed: 34748378
N Engl J Med. 2022 Aug 18;387(7):599-610
pubmed: 36070710
Biomed Pharmacother. 2021 Jun;138:111437
pubmed: 33691249
N Engl J Med. 2021 May 6;384(18):1774-1775
pubmed: 33755376
BJPsych Open. 2021 Dec 03;8(1):e6
pubmed: 34859759
Lancet Glob Health. 2022 Jan;10(1):e42-e51
pubmed: 34717820
Front Pharmacol. 2022 Jan 19;12:755600
pubmed: 35126106